I don't think this is over yet.

I think that there was an element of tiredness with all the recalls.

They have painted themselves into a corner. They have articulated a position and set a price that is well below $72, so it is going to be tough.

At the end of the day, Boston is going to run out of cash ahead of J&J. Boston's really going to have to go for broke.

J&J is flexing its muscles. That's why J&J has come back so aggressively.

Really, Abbott is bearing the brunt of this.

The lion's share of what will be divested is going to Abbott.

I just don't think this is over yet. Boston really feels this is a redefining move for them.

I would not be surprised to see J&J come back. They've got $16 billion in cash at the end of 2005. They have tremendous financial resources. It's up to them.